Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Multicenter, Randomized, Open-Label, Controlled Study of ZG006 for Injection Versus Investigator-Selected Chemotherapy in Participants With Advanced Neuroendocrine Carcinoma

NCT07595913 is registered in ClinicalTrials.gov with Suzhou Zelgen Biopharmaceuticals Co.,Ltd as lead sponsor.

NCT NCT07595913
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07595913 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Multicenter, Randomized, Open-Label, Controlled Study of ZG006 for Injection Versus Investigator-Selected Chemotherapy in Participants With Advanced Neuroendocrine Carcinoma
Lead sponsor
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase
Phase 3
Overall status
Not yet recruiting
Start date
July 31, 2026
Completion date
December 31, 2028
Enrollment
240 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neuroendocrine carcinoma